New drugs for breast cancer
- 7 September 2002
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 360 (9335) , 790-792
- https://doi.org/10.1016/s0140-6736(02)09903-8
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialJournal of Clinical Oncology, 2002
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJournal of Clinical Oncology, 2001
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability StudyJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancerAnnals of Oncology, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999